Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

The new version of syngo.via supports treatment decision-making in oncology

17.06.2015
  • Diagnostics software supports informed treatment decision-making and comprehensive treatment planning by compiling information from different imaging modalities
  • Early checking of treatment by means of a quantitative evaluation of the success of the treatment
  • Offline functionality for the interdisciplinary exchange of information


Cancer treatment is complex. The widely varying progressions of this disease require comprehensive diagnostics, an early check of treatment, and the exchange of information with colleagues. The new version of the diagnostics software syngo.via supports the treating physician in making decisions regarding treatment in oncology through a comprehensive portfolio of applications across imaging systems, treatments, and disciplines.


The new syngo.via – easier than ever

Discover a whole new user experience with syngo.via. You will love the refreshed look and feel and the intuitive operation. Also new: a Google-like search with the Patient Browser.


Imaging procedures play an important role in treatment planning. Multimodal image material not only provides information for a precise assessment of the tumor with regard to its position, morphology and metabolism, but it also forms the basis for radiotherapy planning. The application syngo.via RT Image Suite supports the radiotherapy oncologists in the demanding task of optimally using clinical images from various sources such as CT, MRT or PET-CT in order to contour the tumor to be irradiated and the surrounding tissue to be spared.

Another part of the oncology software portfolio is the application syngo.MR OncoCare. It allows an early, quantitative evaluation of the response of the tumor to the treatment. Thus, conclusions can be drawn about the success of the selected treatment method and, if necessary, this method can be adapted. Thus, the patient is spared from the continuation of ineffective treatment and the unnecessary costs associated with it.

In order to define the best possible treatment for each individual patient and successfully treat cancer, a wide variety of medical disciplines are drawn upon. Their representatives come together in regular, interdisciplinary meetings on this topic in so-called tumor boards. Syngo.MI Offline Oncoboard provides an IT solution in order to be able to present syngo.via findings of the various imaging procedures even on a standard PC and independently of a network connection.

syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via and the syngo.via based software options are not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

You can find further information under www.siemens.com/syngo.via


Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide on a continuing basis.

Further information is available on the Internet at www.siemens.com


Reference Number: PR2015060254HCEN


Contact
Mr. Thorsten Opderbeck
Healthcare
Siemens AG

Henkestr. 127

91052 Erlangen

Germany

Tel: +49 (9131) 84-4906

thorsten.opderbeck​@siemens.com

Thorsten Opderbeck | Siemens Healthcare

More articles from Medical Engineering:

nachricht New insight into the brain’s hidden depths: Jena scientists develop minimally-invasive endoscope
27.11.2018 | Leibniz-Institut für Photonische Technologien e. V.

nachricht New China and US studies back use of pulse oximeters for assessing blood pressure
21.11.2018 | University of British Columbia

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>